Drug Trial Radar · NCT06591845
Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Sep 25, 2024
Primary completion
Dec 16, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, partially double-blind, placebo and active-controlled, 4-period crossover design thorough QT/QTc (TQT) clinical study to evaluate the effects of ziresovir on cardiac repolarization in healthy subjects.
Conditions
- Healthy Volunteers
Interventions
Ziresovir 125 mgDrug
Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
Ziresovir 500 mgDrug
Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
PlaceboDrug
Active Substance: Placebo, Pharmaceutical Form: Suspension, Route of Administration: Oral
Moxifloxacin hydrochloride tablet 400 mgDrug
Active Substance: Moxifloxacin hydrochloride Pharmaceutical Form: Tablet Route of Administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline QTcF (ΔQTcF)Time frame: Before dosing (Baseline) through 48 hours after the dose on Day 1 in each treatment period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
California Clinical Trials Medical Group, Inc.
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.